相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Arsenic Trioxide Rescues Structural p53 Mutations through a Cryptic Allosteric Site
Shuo Chen et al.
CANCER CELL (2021)
Long-Term (≥4 Year and ≥5 Year) Overall Survival (OS) By 12-and 24-Month Event-Free Survival (EFS): An Updated Analysis of ZUMA-1, the Pivotal Study of Axicabtagene Ciloleucel (Axi- Cel) in Patients (Pts) with Refractory Large B-Cell Lymphoma (LBCL)
Caron Jacobson et al.
BLOOD (2021)
CAR T cells with dual targeting of CD19 and CD22 in pediatric and young adult patients with relapsed or refractory B cell acute lymphoblastic leukemia: a phase 1 trial
Shaun Cordoba et al.
NATURE MEDICINE (2021)
CAR T cells with dual targeting of CD19 and CD22 in adult patients with recurrent or refractory B cell malignancies: a phase 1 trial
Jay Y. Spiegel et al.
NATURE MEDICINE (2021)
KMT2D mutations and TP53 disruptions are poor prognostic biomarkers in mantle cell lymphoma receiving high-dose therapy: a FIL study
Simone Ferrero et al.
HAEMATOLOGICA (2020)
Efficacy and safety of CAR19/22 T-cell cocktail therapy in patients with refractory/relapsed B-cell malignancies
Na Wang et al.
BLOOD (2020)
Standard-of-Care Axicabtagene Ciloleucel for Relapsed or Refractory Large B-Cell Lymphoma: Results From the US Lymphoma CAR T Consortium
Loretta J. Nastoupil et al.
JOURNAL OF CLINICAL ONCOLOGY (2020)
Detection and Quantification of Chimeric Antigen Receptor Transgene Copy Number by Droplet Digital PCR versus Real-Time PCR
Yaoyao Lou et al.
JOURNAL OF MOLECULAR DIAGNOSTICS (2020)
Frequent occurrence of CD19-negative relapse after CD19 CAR T and consolidation therapy in 14 TP53-mutated r/r B-ALL children
Jing Pan et al.
LEUKEMIA (2020)
CAR T-cell therapy for a relapsed/refractory acute B-cell lymphoblastic lymphoma patient in the context of Li-Fraumeni syndrome
Liting Chen et al.
JOURNAL FOR IMMUNOTHERAPY OF CANCER (2020)
Functional Classification of TP53 Mutations in Acute Myeloid Leukemia
Sayantanee Dutta et al.
CANCERS (2020)
Commercialanti-CD19 CART cell therapy for patients with relapsed/refractory aggressive B cell lymphoma in a European center
Pierre Sesques et al.
AMERICAN JOURNAL OF HEMATOLOGY (2020)
Genetic and evolutionary patterns of treatment resistance in relapsed B-cell lymphoma
Christopher K. Rushton et al.
BLOOD ADVANCES (2020)
Efficacy and safety of anti-CD19 CAR T-cell therapy in 110 patients with B-cell acute lymphoblastic leukemia with high-risk features
Xian Zhang et al.
BLOOD ADVANCES (2020)
Long-term outcomes of relapsed/refractory double-hit lymphoma (r/r DHL) treated with CD19/22 CAR T-cell cocktail therapy
Jia Wei et al.
CLINICAL AND TRANSLATIONAL MEDICINE (2020)
Predictive factors of early progression after CAR T-cell therapy in relapsed/refractory diffuse large B-cell lymphoma
Laetitia Vercellino et al.
BLOOD ADVANCES (2020)
Interim Analysis of ZUMA-12: A Phase 2 Study of Axicabtagene Ciloleucel (Axi-Cel) as First-Line Therapy in Patients (Pts) With High-Risk Large B Cell Lymphoma (LBCL)
Sattva S. Neelapu et al.
BLOOD (2020)
p53: 800 million years of evolution and 40 years of discovery
Arnold J. Levine
NATURE REVIEWS CANCER (2020)
Genetic alterations and their clinical implications in DLBCL
Yi Miao et al.
NATURE REVIEWS CLINICAL ONCOLOGY (2019)
A Gain-of-Function p53-Mutant Oncogene Promotes Cell Fate Plasticity and Myeloid Leukemia through the Pluripotency Factor FOXH1
Evangelia Loizou et al.
CANCER DISCOVERY (2019)
CD19 CAR T cells following autologous transplantation in poor-risk relapsed and refractory B-cell non-Hodgkin lymphoma
Craig S. Sauter et al.
BLOOD (2019)
Long-term safety and activity of axicabtagene ciloleucel in refractory large B-cell lymphoma (ZUMA-1): a single-arm, multicentre, phase 1-2 trial
Frederick L. Locke et al.
LANCET ONCOLOGY (2019)
CD22-targeted CAR T cells induce remission in B-ALL that is naive or resistant to CD19-targeted CAR immunotherapy
Terry J. Fry et al.
NATURE MEDICINE (2018)
Lenalidomide plus bendamustine-rituximab does not overcome the adverse impact of TP53 mutations in mantle cell lymphoma
Christian Winther Eskelund et al.
HAEMATOLOGICA (2018)
TP53 Germline Variations Influence the Predisposition and Prognosis of B-Cell Acute Lymphoblastic Leukemia in Children
Maoxiang Qian et al.
JOURNAL OF CLINICAL ONCOLOGY (2018)
Monocyte-derived IL-1 and IL-6 are differentially required for cytokine-release syndrome and neurotoxicity due to CAR T cells
Margherita Norelli et al.
NATURE MEDICINE (2018)
CAR T cell-induced cytokine release syndrome is mediated by macrophages and abated by IL-1 blockade
Theodoros Giavridis et al.
NATURE MEDICINE (2018)
Lenalidomide plus bendamustine-rituximab does not overcome the adverse impact of TP53 mutations in mantle cell lymphoma
Christian Winther Eskelund et al.
HAEMATOLOGICA (2018)
Integrated genomic analysis identifies deregulated JAK/STAT-MYC-biosynthesis axis in aggressive NK-cell leukemia
Liang Huang et al.
CELL RESEARCH (2018)
Genomics of aggressive B-cell lymphoma
Allison Rosenthal et al.
HEMATOLOGY-AMERICAN SOCIETY OF HEMATOLOGY EDUCATION PROGRAM (2018)
BIODLCL04: THE PROGNOSTIC ROLE OF CELL OF ORIGIN PROFILE, MYC, BCL2, AND TP53 IN UNTREATED POOR-RISK DIFFUSE LARGE B-CELL LYMPHOMA
A. Chiappella et al.
HEMATOLOGICAL ONCOLOGY (2017)
TP53 mutation and survival in aggressive B cell lymphoma
Thorsten Zenz et al.
INTERNATIONAL JOURNAL OF CANCER (2017)
Rituximab-dose-dense chemotherapy with or without high-dose chemotherapy plus autologous stem-cell transplantation in high-risk diffuse large B-cell lymphoma (DLCL04): final results of a multicentre, open-label, randomised, controlled, phase 3 study
Annalisa Chiappella et al.
LANCET ONCOLOGY (2017)
Axicabtagene Ciloleucel CAR T-Cell Therapy in Refractory Large B-Cell Lymphoma
S. S. Neelapu et al.
NEW ENGLAND JOURNAL OF MEDICINE (2017)
Tumor protein 53 mutations are enriched in diffuse large B-cell lymphoma with irregular CD19 marker expression
Marina Kazantseva et al.
SCIENTIFIC REPORTS (2017)
TP53 mutations identify younger mantle cell lymphoma patients who do not benefit from intensive chemoimmunotherapy
Christian W. Eskelund et al.
BLOOD (2017)
Outcomes in refractory diffuse large B-cell lymphoma: results from the international SCHOLAR-1 study
Michael Crump et al.
BLOOD (2017)
Genetic Landscapes of Relapsed and Refractory Diffuse Large B-Cell Lymphomas
Ryan D. Morin et al.
CLINICAL CANCER RESEARCH (2016)
Phase 1 studies of central memory-derived CD19 CAR T-cell therapy following autologous HSCT in patients with B-cell NHL
Xiuli Wang et al.
BLOOD (2016)
Mutations or copy number losses of CD58 and TP53 genes in diffuse large B cell lymphoma are independent unfavorable prognostic factors
Yang Cao et al.
ONCOTARGET (2016)
Somatic TP53 Mutations in the Era of Genome Sequencing
Pierre Hainaut et al.
COLD SPRING HARBOR PERSPECTIVES IN MEDICINE (2016)
Clinical Outcomes of TP53 Mutations in Cancers
Ana I. Robles et al.
COLD SPRING HARBOR PERSPECTIVES IN MEDICINE (2016)
High-dose cytarabine does not overcome the adverse prognostic value of CDKN2A and TP53 deletions in mantle cell lymphoma
Marie-Helene Delfau-Larue et al.
BLOOD (2015)
Evolution to plasmablastic lymphoma evades CD19-directed chimeric antigen receptor T cells
Andrew G. Evans et al.
BRITISH JOURNAL OF HAEMATOLOGY (2015)
Evolutionary Action Score of TP53 Identifies High-Risk Mutations Associated with Decreased Survival and Increased Distant Metastases in Head and Neck Cancer
David M. Neskey et al.
CANCER RESEARCH (2015)
Role of TP53 mutations in the origin and evolution of therapy-related acute myeloid leukaemia
Terrence N. Wong et al.
NATURE (2015)
Dysfunction of the TP53 tumor suppressor gene in lymphoid malignancies
Zijun Y. Xu-Monette et al.
BLOOD (2012)
Mutational profile and prognostic significance of TP53 in diffuse large B-cell lymphoma patients treated with R-CHOP: report from an International DLBCL Rituximab-CHOP Consortium Program Study
Zijun Y. Xu-Monette et al.
BLOOD (2012)
Analysis of the coding genome of diffuse large B-cell lymphoma
Laura Pasqualucci et al.
NATURE GENETICS (2011)
Immunotherapy following hematopoietic stem cell transplantation: potential for synergistic effects
Myriam N. Bouchlaka et al.
IMMUNOTHERAPY (2010)
Salvage Regimens With Autologous Transplantation for Relapsed Large B-Cell Lymphoma in the Rituximab Era
Christian Gisselbrecht et al.
JOURNAL OF CLINICAL ONCOLOGY (2010)
Mutant p53 Gain-of-Function in Cancer
Moshe Oren et al.
COLD SPRING HARBOR PERSPECTIVES IN BIOLOGY (2010)
Blinded by the Light: The Growing Complexity of p53
Karen H. Vousden et al.
CELL (2009)
The first 30 years of p53: growing ever more complex
Arnold J. Levine et al.
NATURE REVIEWS CANCER (2009)
Adoptive Cell Therapy for Patients With Metastatic Melanoma: Evaluation of Intensive Myeloablative Chemoradiation Preparative Regimens
Mark E. Dudley et al.
JOURNAL OF CLINICAL ONCOLOGY (2008)
TP53 mutations and survival in squamous-cell carcinoma of the head and neck
M. Luana Poeta et al.
NEW ENGLAND JOURNAL OF MEDICINE (2007)
Removal of homeostatic cytokine sinks by lymphodepletion enhances the efficacy of adoptively transferred tumor-specific CD8+ T cells
L Gattinoni et al.
JOURNAL OF EXPERIMENTAL MEDICINE (2005)
Less is more: lymphodepletion followed by hematopoietic stem cell transplant augments adoptive T-cell-based anti-tumor immunotherapy
C Wrzesinski et al.
CURRENT OPINION IN IMMUNOLOGY (2005)
Concomitant tumor immunity to a poorly immunogenic melanoma is prevented by regulatory T cells
MJ Turk et al.
JOURNAL OF EXPERIMENTAL MEDICINE (2004)
分享论文
